A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: Results of the Panitumumab, Irinotecan and Ciclosporin in COLOrectal cancer therapy trial (PICCOLO)

A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: Results of the Panitumumab, Irinotecan and Ciclosporin in COLOrectal cancer therapy trial (PICCOLO)

Show other versions (1)

Background The main toxicity of irinotecan in advanced colorectal cancer (CRC) is delayed diarrhoea. Intestinal SN-38, released by deconjugation of the parent glucuronide excreted into the bile or produced in situ by intestinal carboxylesterase, is toxic to the intestinal epithelium. The canalicular...

Full description

Bibliographic Details
Main Authors: Middleton, G, Brown, S, Lowe, C, Maughan, T, Gwyther, S, Oliver, A, Richman, S, Blake, D, Napp, V, Marshall, H, Wadsley, J, Maisey, N, Chau, I, Hill, M, Gollins, S, Myint, S, Slater, S, Wagstaff, J, Bridgewater, J, Seymour, M
Format: Journal article
Language:English
Published: 2013

Similar Items